Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium
- Development stage
- Unknown
- Lead developer
- Prodia Stem Cell Indonesia
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intralesional
01
Overview
This investigational cell-based and secretome-based therapy is being developed by PT. Prodia Stem Cell Indonesia (ProSTEM) for the treatment of keloids. The therapy consists of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) isolated from Wharton's Jelly and their corresponding conditioned medium (UC-CM). Administered via intralesional injection directly into keloid tissue, the therapy leverages the immunomodulatory and regenerative properties of mesenchymal stem cells and their secreted paracrine factors. The biological mechanism aims to modulate collagen production and reduce the activation of keloid fibroblasts, thereby promoting keloid regression. It is currently being evaluated in Phase 1/2 clinical trials as a potential alternative to standard triamcinolone acetonide treatments.
- Other names
- UC-MSCs and UC-CMUC-MSCs and CM UC-MSCsUmbilical Cord-Mesenchymal Stem Cells and Conditioned Mediumumbilical cord-mesenchymal stem cells and conditioned medium-PT. Prodia Stem Cell Indonesia-keloid
Beyond the preview
Go deeper on Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium.